Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 24Urinary Bladder Neoplasms 22Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Peripheral Nervous System Diseases 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1

Interventions

Cisplatin 6pembrolizumab 5fludarabine 5Nivolumab 5Cyclophosphamide 5aldesleukin 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Radiotherapy 3Ipilimumab 3fludarabine phosphate 2entinostat 2cabozantinib 2avelumab 2aflibercept 2Specimen Handling 2CTLA-4 Antigen 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1ripretinib 1oncogene protein E7, Human papillomavirus type 16 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Penile Neoplasms × enfortumab vedotin × Clear all
NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic

Phase 2 Recruiting
28 enrolled
Genitourinary

Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡